Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy
Open Access
- 15 May 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (1) , 135-142
Abstract
Summary: Background: Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose‐optimisation for ustekinumab nonresponse is limited.Aim: To assess the effectiveness of dose escalation of ustekinumab.Methods: This was a multicentre retrospective cohort study. We included active Crohn's disease patients who received a standard‐dose intravenous induction and at least one subcutaneous ustekinumab 90 mg dose. All enrolled patients received dose escalation by either shortening the interval between the doses to every 4 or 6 weeks, intravenous reinduction or a combination of strategies. The primary outcome of the study was clinical response at week 16 after dose escalation.Results: A total of 142 patients (22 centres/14 countries) were included. The patients were dose‐escalated after a median treatment duration of 30 weeks. At week 16 from escalation, 73/142 (51.4%) responded to treatment, including 55/142 (38.7%) in clinical remission. Corticosteroid‐free remission was achieved in 6/34 (17.6%) patients on corticosteroids at the time of escalation; 118/142 (83%) continued treatment beyond week 16. Follow‐up data beyond week 16 were available for 74/118 (62.7%) patients. On the last follow‐up, 51/98 (52%) patients with available data responded to treatment, including 41/98 (42%) in clinical remission.Conclusions: Intensification of ustekinumab maintenance dosage was effective in over 50% of the patients. This strategy should be considered in patients who are nonresponsive to every 8 weeks ustekinumab maintenance dosing.Keywords
This publication has 27 references indexed in Scilit:
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2019
- Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidenceDigestive and Liver Disease, 2019
- Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease CenterJournal of Pediatric Gastroenterology and Nutrition, 2019
- Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyJournal of Crohn's and Colitis, 2019
- Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn’s Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral CenterGastroenterology Research, 2019
- Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s DiseaseGastroenterology, 2018
- Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapyAlimentary Pharmacology & Therapeutics, 2018
- Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2017
- Patients with Refractory Crohnʼs Disease Successfully Treated with UstekinumabInflammatory Bowel Diseases, 2016
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseNew England Journal of Medicine, 2012